Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial (Q38380059)

From Wikidata

Jump to navigation Jump to search

scientific article published on 02 March 2017

Language	Label	Description	Also known as
English	Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial	scientific article published on 02 March 2017

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

3 July 2018

http://europepmc.org/abstract/PMC/5824321

Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial (English)

1 reference

Europe PubMed Central

PMC publication ID

3 July 2018

http://europepmc.org/abstract/PMC/5824321

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PMC publication ID

3 July 2018

http://europepmc.org/abstract/PMC/5824321

15

1 reference

Europe PubMed Central

PMC publication ID

3 July 2018

http://europepmc.org/abstract/PMC/5824321

object named as

Jouni Junnila

16

0 references

Arja Jukkola-Vuorinen

4

object named as

Arja Jukkola-Vuorinen

1 reference

Europe PubMed Central

PMC publication ID

3 July 2018

Pirkko-Liisa Kellokumpu-Lehtinen

2

object named as

Pirkko-Liisa Kellokumpu-Lehtinen

1 reference

Europe PubMed Central

PMC publication ID

3 July 2018

http://europepmc.org/abstract/PMC/5824321

17

object named as

Petri Bono

1 reference

Europe PubMed Central

PMC publication ID

3 July 2018

http://europepmc.org/abstract/PMC/5824321

Riikka Huovinen

3

object named as

Riikka Huovinen

1 reference

Europe PubMed Central

PMC publication ID

3 July 2018

http://europepmc.org/abstract/PMC/5824321

5

object named as

Minna Tanner

1 reference

Europe PubMed Central

PMC publication ID

3 July 2018

http://europepmc.org/abstract/PMC/5824321

6

object named as

Riitta Kokko

1 reference

Europe PubMed Central

PMC publication ID

3 July 2018

http://europepmc.org/abstract/PMC/5824321

7

object named as

Johan Ahlgren

1 reference

Europe PubMed Central

PMC publication ID

3 July 2018

http://europepmc.org/abstract/PMC/5824321

8

object named as

Päivi Auvinen

1 reference

Europe PubMed Central

PMC publication ID

3 July 2018

http://europepmc.org/abstract/PMC/5824321

Kenneth Villman

11

object named as

Kenneth Villman

1 reference

Europe PubMed Central

PMC publication ID

3 July 2018

http://europepmc.org/abstract/PMC/5824321

12

object named as

Paul Nyandoto

1 reference

Europe PubMed Central

PMC publication ID

3 July 2018

http://europepmc.org/abstract/PMC/5824321

13

object named as

Greger Nilsson

1 reference

Europe PubMed Central

PMC publication ID

3 July 2018

http://europepmc.org/abstract/PMC/5824321

author name string

Outi Lahdenperä

9

1 reference

Europe PubMed Central

PMC publication ID

3 July 2018

http://europepmc.org/abstract/PMC/5824321

Sanna Kosonen

10

1 reference

Europe PubMed Central

PMC publication ID

3 July 2018

http://europepmc.org/abstract/PMC/5824321

Paula Poikonen-Saksela

14

1 reference

Europe PubMed Central

PMC publication ID

3 July 2018

http://europepmc.org/abstract/PMC/5824321

Henrik Lindman

18

1 reference

Europe PubMed Central

PMC publication ID

3 July 2018

http://europepmc.org/abstract/PMC/5824321

publication date

1 June 2017

1 reference

Europe PubMed Central

PMC publication ID

3 July 2018

http://europepmc.org/abstract/PMC/5824321

1 reference

Europe PubMed Central

PMC publication ID

3 July 2018

http://europepmc.org/abstract/PMC/5824321

3

1 reference

Europe PubMed Central

PMC publication ID

3 July 2018

http://europepmc.org/abstract/PMC/5824321

6

1 reference

Europe PubMed Central

PMC publication ID

3 July 2018

http://europepmc.org/abstract/PMC/5824321

793-800

1 reference

Europe PubMed Central

PMC publication ID

3 July 2018

http://europepmc.org/abstract/PMC/5824321

Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824321

10 July 2018

A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824321

10 July 2018

Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824321

10 July 2018

Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824321

10 July 2018

A Majority of Low (1-10%) ER Positive Breast Cancers Behave Like Hormone Receptor Negative Tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824321

10 July 2018

A three-arm randomized phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxel plus capecitabine in patients with metastatic breast cancer previously treated with anthracyclines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824321

10 July 2018

Comprehensive molecular portraits of human breast tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824321

10 July 2018

Bevacizumab added to neoadjuvant chemotherapy for breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824321

10 July 2018

Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824321

10 July 2018

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824321

10 July 2018

Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824321

10 July 2018

Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824321

10 July 2018

Adjuvant chemotherapy in older women with early-stage breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824321

10 July 2018

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824321

10 July 2018

Baseline staging tests in primary breast cancer: a practice guideline

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824321

10 July 2018

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824321

10 July 2018

Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824321

31 August 2018

Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824321

31 August 2018

Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824321

31 August 2018

Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824321

31 August 2018

Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824321

31 August 2018

Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5824321

3 December 2018

Staging of breast cancer: new recommended standard procedure

1 reference

https://pubmed.ncbi.nlm.nih.gov/28253390

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/28253390

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models

1 reference

https://pubmed.ncbi.nlm.nih.gov/28253390

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biochemical and clinical pharmacology of 5-fluorouracil

1 reference

https://pubmed.ncbi.nlm.nih.gov/28253390

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1001/JAMAONCOL.2016.6120

1 reference

Europe PubMed Central

PMC publication ID

3 July 2018

http://europepmc.org/abstract/PMC/5824321

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

3 July 2018

http://europepmc.org/abstract/PMC/5824321

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

3 July 2018

http://europepmc.org/abstract/PMC/5824321

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38380059&oldid=2056365094"